Veracyte’s TrueMRD Medicare win pushes whole-genome MRD testing into bladder cancer surveillance
MRD testing is moving from research to reimbursement. Veracyte now has Medicare coverage, but adoption in bladder cancer care is the harder test.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Why Veracyte’s Medicare win for TrueMRD could reshape bladder cancer recurrence monitoring
MRD testing has payer momentum, but clinical adoption is tougher. Veracyte’s TrueMRD Medicare win puts bladder cancer monitoring in focus.